doi: 10.3390/ijms22126332 146 ThomasMKNikooienejadABrayRCuiXWilsonJDuffinKet al
Open 27 , bio029660 (2018)
10 Conclusions and clinical take-home messages 10.1 Main findings: certainties amidst uncertainties Synthesizing the current evidence, the information architecture regarding GLP-1RAs in PCOS fertility management exhibits a characteristic gradient: robust metabolic evidence, hypothesis-generating reproductive findings, and a gray zone of safety. Robust metabolic benefit: in overweight or obese PCOS phenotypes, evidence for the improvement of metabolic endpointsincluding body weight, central adiposity, and IRis consistently positive, facilitating the establishment of actionable therapeutic goals (e.g., reaching clinically significant weight-loss thresholds and optimizing IR markers)
J Basic Microbiol 54(Suppl 1):S190S199
PlexusDx's Precision Peptide Genetic Test identifies your genetic predispositions across 14 metabolic pathwaysincluding variants in GLP1R, GIPR, FTO, and MC4Rallowing your provider to select the optimal GLP-1 compound (semaglutide injection, oral semaglutide, tirzepatide, or GLP-Squared) and dosing strategy tailored to your biology